ERBB2 and breast cancer: In 2020, Montemurro et al. (2020) conducted the KAMILLA study involving 398 patients with HER2+ advanced or brain–metastatic breast cancer and yielded promising results, pointing toward the potential of T-DM1 in treating HER2+ metastatic BC.